What does AnGes, Inc. do?
AnGes, Inc. engages in the research and development of gene-based medicines. It develops HGF gene therapy product for the treatment of chronic arterial occlusive disease; NF-KB decoy oligonucleotide for chronic discogenic lumbar back pain; and DNA vaccines for the treatment of hypertension, as well as tie2 agonists…
What is AnGes, Inc.'s P/E and P/B ratio?
AnGes, Inc. has a P/E ratio of -3.1 and a P/B ratio of 56.23.
What is AnGes, Inc.'s debt-to-equity ratio?
AnGes, Inc. has a debt-to-equity ratio of 3.52.
How much does AnGes, Inc. owe compared with what it owns?
AnGes, Inc. owes ¥0.94 for every ¥1 it owns (balance sheet Jun 2026), which is high.
What is AnGes, Inc.'s Positivity rank?
AnGes, Inc. is ranked #10,271 of 10,750 companies globally and #3,666 of 3,683 in Japan on PositoAI, with a Positivity Score of -9,627.
Does AnGes, Inc. have any regulatory orders, red flags (PosiRed) or yellow flags (PosiYellow)?
Red flags (PosiRed) are not checked yet for companies in this market on PositoAI, so no result is shown for AnGes, Inc..
Where can I read the latest news about AnGes, Inc.?
Recent headlines about AnGes, Inc. from the last 30 days, with links to the original articles, are on its News page on PositoAI.
Does AnGes, Inc. have a PositoAI PosiShot or QR code?
Yes. A dated PosiShot of AnGes, Inc.'s current position, a PosiQR code for its live profile and a ready-made dated mention are available on its For this company page on PositoAI.